Comparative genomic hybridization analysis of chromosomal changes occurring during development of acquired resistance to cisplatin in human ovarian carcinoma cells

Genes Chromosomes and Cancer

Volumn 18, Issue 4, 1997, Pages 286-291

  Wasenius, Veli Matti ^a   Jekunen, Antti ^a   Monni, Outi ^b   Joensuu, Heikki ^a   Aebi, Stefen ^c   Howell, Stephen B ^c   Knuutila, Sakari ^b  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMONY DERIVATIVE; ARSENIC TRIOXIDE; CISPLATIN; DNA;

ARTICLE; CARCINOMA CELL; CHROMOSOME ABERRATION; CHROMOSOME DELETION; CONTROLLED STUDY; CROSS RESISTANCE; DNA HYBRIDIZATION; DNA SEQUENCE; DRUG RESISTANCE; HUMAN; HUMAN CELL; OVARY CARCINOMA; PRIORITY JOURNAL;

CHROMOSOME ABERRATIONS; CHROMOSOME BANDING; CHROMOSOME MAPPING; CISPLATIN; DNA, NEOPLASM; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; NUCLEIC ACID HYBRIDIZATION; OVARIAN NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0030966025     PISSN: 10452257     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2264(199704)18:4<286::AID-GCC6>3.0.CO;2-X     Document Type: Article

References (17)

1. Andrews PA, Howell SB (1990) Cellular pharmacology of cis-platin: Perspectives on mechanism of acquired resistance. Cancer Cells 2:35-43.
2. Andrews PA, Murphy MP, Howell SB (1985) Differential potentiation of alkylating agent cytotoxicity in human ovarian carcinoma cells by glutathione depletion. Cancer Res 45:6250-6253.
3. Behrens BC, Hamilton TC, Masuda H, Grotzinger KR, Whang-Peng J, Louie KG, Knutzen T, McKoy RC, Ozols RF (1987) Characterization of a cis-diamminedichloro-platinum (II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res 47:414-418.
4. Christen RD, Jekunen AP, Jones JA, Thiebaut F, Shalinsky DR, Howell SB (1993) In vitro modulation of cisplatin accumulation in human ovarian carcinoma cells by pharmacologic alteration of microtubules. J Clin Invest 92:431-440.
5. Christen RD, Isonishi S, Jones JA, Jekunen AJ, Hom DK, Kröning R, Gateky DP, Thienaut FB, Los G, Howell SB (1994) Signaling and drug sensitivity. Cancer Metastasis Rev 13:175-189.
6. Disaia PJ, Sinkovics JG, Rutledge FN, Smith JP (1972) Cell-mediated immunity to human malignant cells. Am J Obstet Gynecol 114:979-989.
7. Gately DP, Howell SB (1993) Cellular accumulation of the anticancer agent cisplatin: A review. Br J Cancer 67:1171-1176.
8. Grant CE, Valdimarsson G, Hipfner DR, Almquist KC, Cole SP, Deeley RG (1994) Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res 15:357-361.
9. Isonishi S, Jekunen AP, Hom DK, Eastman A, Edelstein PS, Thiebaut FB, Christen RD, Howell SB (1992) Modulation of cisplatin sensitivity and growth rate of an ovarian carcinoma cell line by homhesin and tumor necrosis factor-α. J Clin Invest 90:1436-1442.
10. Jekunen AP, Vick J, Sanga R, Chan TCK, Howell SB (1992) Synergism between dipyridamole and cisplatin in human ovarian carcinoma cells in vitro. Cancer Res 52:3566-3571.
11. Jekunen AP, Christen RD, Shalinsky DR, Howell SB (1994) Synergistic interaction between cisplatin and taxol in human ovarian carcinoma cells in vitro. Br J Cancer 69:299-306.
12. Kallioniemi OP, Kallioniemi A, Piper J, Isola J, Waldman FM, Gray JW, Pinkel D (1994) Optimizing comparative genomic hybridization for analysis of DNA sequence copy number changes in solid tumors. Genes Chromosom Cancer 10:231-243.
13. Naredi P, Heath DD, Enns RE, Howell SB (1994) Cross-resistance between cisplatin and antimony in a human ovarian carcinoma. Cancer Res 54:6464-6468.
14. Naredi P, Heath DD, Enns RE, Howell SB (1995) Cross-resistance between cisplatin, antimony potassium tartrate, and arsenite in human tumor cells. J Clin Invest 95:1193-1198.
15. Sasada T, Iwata S, Sato N, Kitaoka Y, Hirota K, Nakamura K, Nishiyama A, Taniguchi Y, Takabayashi A, Yodoi J (1996) Redox control of resistance to cis-diamminechloroplatinum (II) (CDDP). Protective effect of human thioredoxin against CDDP-induced cytotoxicity. J Clin Invest 97:2268.
16. Schwendel A, Petersen I, Hartman T, Ried T, Dietel M, Lage H (1996) Mapping of DNA gains and losses in parental and multidrug-resistance cancer cell lines (abstract). In: European Congress of Comparative Genomic Hybridization. European Society of Human Genetics, Wien, Austria, March 1996, p 42.
17. Szymanska J, Tarkkanen M, Wiklund T, Virolainen M, Blomqvist C, Asko-Seljavaara S, Tukiainen E, Elomaa I, Knuutila S (1996) Gains and losses of DNA sequences in liposarcomas evaluated by comparative genomic hybridization. Genes Chromosom Cancer 15:89-94.